Acorda Therapeutics Inc (ACOR)

16.50
0.00 (0.00)
NASDAQ : Health Care
Prev Close 16.50
Open 16.45
Day Low/High 16.05 / 16.60
52 Wk Low/High 23.85 / 43.63
Volume 1.00M
Avg Volume 1.23M
Exchange NASDAQ
Shares Outstanding 46.76M
Market Cap 771.51M
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Acorda Provides Financial And Pipeline Update For First Quarter 2017

Acorda Provides Financial And Pipeline Update For First Quarter 2017

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced financial results for its first quarter ended March 31, 2017, and provided an update on the Company's pipeline, financial guidance and corporate restructuring.

Commit To Purchase Acorda Therapeutics At $13, Earn 14.2% Annualized Using Options

Commit To Purchase Acorda Therapeutics At $13, Earn 14.2% Annualized Using Options

Investors considering a purchase of Acorda Therapeutics Inc shares, but tentative about paying the going market price of $16.35/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the October put at the $13 strike, which has a bid at the time of this writing of 90 cents.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AAN, CR, CVLT, CWCO, GPRK, KMB, MDLZ, MVC, OPB, POL, PW, RMBS, SNY Downgrades: ACOR, AKR, FCCY, NRZ, QGEN, SSY, SWFT, TBBK, WRI Initiations: UA Read on to get TheStreet Quant Ratings' detailed report:

Acorda To Host Conference Call To Discuss First Quarter 2017 On April 27, 2017

Acorda To Host Conference Call To Discuss First Quarter 2017 On April 27, 2017

Acorda Therapeutics, Inc. (Nasdaq:ACOR) will host a conference call and webcast to report its first quarter 2017 financial results and pipeline updates on Thursday, April 27 at 8:30 a.

Acorda CEO Risks All, Loses Nothing, When Drug Patent Strategy Backfires, Employees Fired

Acorda CEO Risks All, Loses Nothing, When Drug Patent Strategy Backfires, Employees Fired

Biotech is an inherently risky business, so layoffs are an unfortunate consequence of bad things happening. But Acorda's situation is a different because the company was extra risky from founding.

Acorda Therapeutics Implements Corporate Restructuring To Align Cost Structure With Focus On Promising Late-Stage Programs

Acorda Therapeutics Implements Corporate Restructuring To Align Cost Structure With Focus On Promising Late-Stage Programs

Acorda Therapeutics, Inc. (Nasdaq:  ACOR) today announced a corporate restructuring to reduce its cost structure and focus its resources on its two late-stage programs, CVT-301 and tozadenant, as well as on maximizing...

Acorda Shares Fall 21% on Patent Ruling Loss That Clears Way for MS Generic

Acorda Shares Fall 21% on Patent Ruling Loss That Clears Way for MS Generic

A District Court judge found four Acorda patents on Ampyra were invalid due to obviousness.

U.S. District Court Issues Decision To Invalidate Four AMPYRA Patents; Company Will Appeal Ruling

U.S. District Court Issues Decision To Invalidate Four AMPYRA Patents; Company Will Appeal Ruling

Acorda Therapeutics, Inc. (Nasdaq:  ACOR ) today announced that the United States District Court for the District of Delaware upheld U.

Acorda Therapeutics Sinks on Invalidated Patents

Acorda Therapeutics Sinks on Invalidated Patents

Shares of the biopharmaceutical company were falling over 25% during midday trading.

Figure 1 (Graphic: Business Wire)

Figure 1 (Graphic: Business Wire)

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced results from two ongoing, long-term safety studies of CVT-301 in people with Parkinson's that showed no differences in pulmonary function between the group receiving...

The MS Awareness Facts Skill Allows Users To Ask Amazon Alexa For An MS Awareness Fact To Learn More About Multiple Sclerosis And Find Helpful Information On MS And Its Symptoms.

The MS Awareness Facts Skill Allows Users To Ask Amazon Alexa For An MS Awareness Fact To Learn More About Multiple Sclerosis And Find Helpful Information On MS And Its Symptoms.

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced the launch of its Alexa skill, MS Awareness Facts , as part of the company's activities in recognition of Multiple Sclerosis (MS) Awareness Month.

Patent Trials And Appeal Board (PTAB) Upholds Four AMPYRA® Patents

Patent Trials And Appeal Board (PTAB) Upholds Four AMPYRA® Patents

Acorda Therapeutics, Inc. (Nasdaq:  ACOR ) today announced that the United States Patent and Trademark Office (USPTO) Patent Trials and Appeal Board (PTAB) upheld all four patents challenged via the inter partes...

Acorda Stock Jumps Following Patent Challenge Win

Acorda Stock Jumps Following Patent Challenge Win

The challenge was brough by hedge fund manager Kyle Bass.

Acorda To Present At The Cowen And Company 37th Annual Healthcare Conference

Acorda To Present At The Cowen And Company 37th Annual Healthcare Conference

Acorda Therapeutics, Inc. (Nasdaq: ACOR) will present at the Cowen and Company 37th Annual Health Care Conference in Boston on Monday, March 6, 2017 at 1:20 p.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ACOR, BAM, BCOR, CMFN, GG, INFO, LBTYA, LBTYK, MXC, WNRL Downgrades: AAN, BCOV, DE, GLAD, MCO, ROCK, RPAI, UEIC Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Catherine D. Strader, Ph.D., Joins Acorda Therapeutics Board Of Directors

Catherine D. Strader, Ph.D., Joins Acorda Therapeutics Board Of Directors

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Catherine D.

Analysts' Actions -- Acorda, Restoration Hardware, Humana, Merck and More

Analysts' Actions -- Acorda, Restoration Hardware, Humana, Merck and More

Here are Wednesday's top research calls, including upgrades for Acorda and Restoration Hardware, a price target increase for Humana and a price target cut for Merck.

Acorda Provides Financial And Pipeline Update For Fourth Quarter And Year End 2016

Acorda Provides Financial And Pipeline Update For Fourth Quarter And Year End 2016

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today provided a financial and pipeline update for the fourth quarter and full year ended December 31, 2016.

Acorda Therapeutics Stock Surges on Clinical Trial Results

Acorda Therapeutics Stock Surges on Clinical Trial Results

Acorda Therapeutics announced positive results in a clinical trial for its drug CVT-301.

Acorda, Amgen and Regeneron Lead Premarket Biotech Movers

Acorda, Amgen and Regeneron Lead Premarket Biotech Movers

Acorda was soaring ahead of the market open, thanks to positive late-stage clinical trial results for levodopa.

Acorda Therapeutics Inhaled Drug Reduces Parkinson's Motor Symptoms in Late-Stage Study

Acorda Therapeutics Inhaled Drug Reduces Parkinson's Motor Symptoms in Late-Stage Study

Acorda intends to file for U.S. marketing approval for the drug, CVT-301, in the second quarter, pending results from two long-term safety studies.

Acorda Announces Positive Phase 3 Clinical Trial Results For CVT-301

Acorda Announces Positive Phase 3 Clinical Trial Results For CVT-301

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced Phase 3 clinical data of CVT-301, showing a statistically significant improvement in motor function in people with Parkinson's disease experiencing OFF periods.

Acorda Therapeutics To Present At Two Investor Conferences In February

Acorda Therapeutics To Present At Two Investor Conferences In February

Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that the Company will present at two investor conferences during February.

Acorda To Host Conference Call To Discuss Fourth Quarter 2016 On February 14, 2017

Acorda To Host Conference Call To Discuss Fourth Quarter 2016 On February 14, 2017

Acorda Therapeutics, Inc. (Nasdaq:ACOR) will host a conference call and webcast to report its fourth quarter 2016 financial results and pipeline updates on Tuesday, February 14 at 8:30 a.

First Week of March 17th Options Trading For Acorda Therapeutics (ACOR)

First Week of March 17th Options Trading For Acorda Therapeutics (ACOR)

Investors in Acorda Therapeutics Inc saw new options begin trading this week, for the March 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACOR options chain for the new March 17th contracts and identified one put and one call contract of particular interest.

Acorda Announces 2016 AMPYRA Net Sales And 2017 Financial Guidance At J.P. Morgan Healthcare Conference

Acorda Announces 2016 AMPYRA Net Sales And 2017 Financial Guidance At J.P. Morgan Healthcare Conference

Acorda Therapeutics, Inc. (NASDAQ: ACOR) reported AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg net sales for the fourth quarter of 2016 of $132 million.

17 Thoughts on Biotech Stocks to Kick Off 2017

17 Thoughts on Biotech Stocks to Kick Off 2017

Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.